Genetically Modified CD7-Targeting Allogeneic CAR T Cell Therapy with Enhanced Efficacy for Relapsed/Refractory CD7-Positive Hematological Malignancies: A Phase I Clinical Study

Scientists developed healthy donor-derived, CD7-targeting CAR-T cells with genetic modifications to resist fratricide, graft-versus-host disease and allogeneic rejection, as well as to potentiate antitumor function.